Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220779 · ClinicalTrials.gov registry record · Phase 2
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
A Phase 2 study, sponsored by Grifols Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
NCT00220779: Completed Phase 2 study, sponsored by Grifols Therapeutics.
NCT00220779 is a Phase 2 study that has completed, run by Grifols Therapeutics. The registered enrollment target is 128 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00220779, a Phase 2 study, has completed, sponsored by Grifols Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
Study Summary
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
Primary Outcome
A relapse was defined for the purposes of this study as the appearance or reappearance of one or more neurological symptoms or worsening of an old symptom attributed to multiple sclerosis (MS) persisting for at least 48 hours and immediately preceded by a relatively stable or improving neurological state of at least 30 days.
Interventions
- DRUG Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
- DRUG Albumin (Human) 25%, United States Pharmacopeia (USP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
What the finished NCT00220779 record still lists
NCT00220779 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified is the first listed.
NCT00220779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00220779 about?
NCT00220779 is a clinical study titled "Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis". The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
What is the current status of trial NCT00220779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2002-12. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00220779?
The interventions under investigation include: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified (DRUG), Albumin (Human) 25%, United States Pharmacopeia (USP) (DRUG).
Who is sponsoring clinical trial NCT00220779?
This trial is sponsored by Grifols Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00220779's enrollment target sits among peer trials
128 553rd of 2000 higher than 1,446 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia